Program Description
The role of HER2 in breast cancer pathobiology dictates the use of a range of targeted agents. The classification of HER2-low and HER2-ultralow breast cancer subgroups also drives treatment decisions, raising questions about how best to integrate novel HER2-targeted therapies. Advances in HER2-targeted therapies have significantly improved survival outcomes and new therapeutic possibilities for HER2-expressing metastatic breast cancer. However, this has introduced significant complexity into treatment selection and sequencing. This program will delve into the pharmacology and clinical considerations of various anti-HER2 agents, including monoclonal antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors. A significant focus of the program will be on the pharmacologic management of HER2-expressing metastatic breast cancer, covering frontline standards of care, second-line and subsequent treatment options, and strategies for treatment selection and sequencing, with specific considerations for patients with brain metastases. Through clinical case studies, participants will review best practices to individualize treatment plans based on guidelines, patient-specific factors, and medication characteristics, and to provide comprehensive supportive care.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: July 28, 2025
Expiration date: July 28, 2026
Time to complete activity: 1.5 hours
Learner level: Intermediate, Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
1. Analyze unique properties of HER2-targeted therapies, such as toxicity profiles, dosing, and administration, to ensure safety and efficacy in HER2-expressing metastatic breast cancer treatment
2. Examine therapeutic strategies for managing HER2-expressing metastatic breast cancer to optimize treatment outcomes across the HER2 spectrum
3. Determine effective tactics for adverse effect prevention and management in HER2-expressing metastatic breast cancer, including dose adjustments, supportive care interventions, and patient counseling
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here